Orexo AB (publ) (ORXOF OTCQX) stock market data APIs
$1.0762
0(0%)
as of June 30, 2025
Try our APIs with
free plan!
Orexo AB (publ) Financial Data Overview
Price chart is built with
Anychart
Orexo AB (publ), a specialty pharmaceutical company, develops and commercializes pharmaceuticals and digital therapies in the United States, European Union, the United Kingdom, and internationally. Its products include Zubsolv tablets for the treatment of opioid use disorder; Abstral for the treatment of breakthrough pain in cancer patients; and Edluar for the treatment of insomnia. The company is developing OX124 for opioid overdose; OX125 for rescue medication and opioid overdose; OX640 to treat anaphylaxis with powder-based epinephrine; and OX-MPI for the treatment of endometriosis. In addition, its digital therapies include deprexis for the treatment of depression; vorvida for alcohol management; and modia for opioid use disorder. The company has a collaboration agreement with Abera Bioscience AB to develop nasal powder vaccines based on the AmorphOX technology. Orexo AB (publ) was founded in 1994 and is headquartered in Uppsala, Sweden.
Prev. Close
1.0762
Open
1.0762
High
1.0762
Low
1.0762
52 wk Range
1.08-1.5
Market Cap
64 142 K
Shares Outstanding
34 505 K
Revenue
597 M
EPS
-2.67
Beta
0.512
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Orexo AB (publ) data using free add-ons & libraries
Get Orexo AB (publ) Fundamental Data
Orexo AB (publ) Fundamental data includes:
- Net Revenue: 597 M
- EBITDA: 12 900 K
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2023-01-25
- EPS/Forecast: -1.8
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Orexo AB (publ) News
New
Orexo postpones publication of the Annual Report
UPPSALA, Sweden, March 15, 2023 /PRNewswire/ -- Orexo AB (publ), (STO:ORX) (OTCQX:ORXOY), has resolved to postpone the publication of the Annual Report for 2022 to March 28, 2023. The previously anno...
Notice of Annual General Meeting of Orexo
UPPSALA, Sweden, March 15, 2023 /PRNewswire/ -- The shareholders in Orexo AB (publ), reg. no. 556500-0600, registered office Uppsala, are summoned to the annual general meeting, to be held o...
Orexo submits New Drug Application to FDA for OX124, a high-dose rescue medication for opioid overdose
OX124 is designed to reverse the effects of the most powerful synthetic opioids, such as fentanyl Nine out of ten fatal opioid overdoses in the US involve synthetic opioids If approved, the US launch...
Orexo Interim Report Q4 2022, incl. Full Year Report
UPPSALA, Sweden, Jan. 26, 2023 /PRNewswire/ -- Important steps forward in a challenging environment Q4 2022 highlights Total net revenues of SEK 156.1 m (144.0) EBITDA of SEK -53.1 m (-48.5), EBI...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
